Ky­owa Hakko Kirin hit with a new PhI­II set­back on an old Parkin­son’s drug

Eight years af­ter Japan’s Ky­owa Hakko Kirin was hand­ed an FDA re­jec­tion for its Parkin­son’s drug istrade­fylline (KW-6002), re­searchers say they record­ed a Phase III flop for the drug.

The drug, ap­proved in Japan, is de­signed to re­duce the amount of dai­ly off-time pa­tients ex­pe­ri­ence with lev­odopa. But while Ky­owa Hakko’s team tracked a trend in fa­vor of the 20 mg and 40 mg dos­es, they did not hit sta­tis­ti­cal sig­nif­i­cance.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.